Last reviewed · How we verify

NCT05049174

Nurse-led Smoking Cessation Program With Follow-up in Healthy Life Centres: a Randomized Clinical Trial

Status unknown NA Last updated 13 March 2024
What this trial tests

NA trial testing Nuse-led interview and referral to municipal healthy life-centres in Smoking Cessation in 221 participants. Status unknown.

Timeline
1 November 2021
Primary endpoint
30 April 2024
30 April 2024

Quick facts

Lead sponsorVestre Viken Hospital Trust
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment221
Start date1 November 2021
Primary completion30 April 2024
Estimated completion30 April 2024
Sites3 locations across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Vestre Viken Hospital Trust

Who can join

18 and older, any sex, with Smoking Cessation or Smoking Behaviors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A better understanding of how to incorporate effective smoking cessation measures into clinical practice is requested. In this is prospective, multi-center, randomized, open, blinded end-point (PROBE) trial, we assigned daily smokers hospitalized with an acute cardiac event 1:1 to an in-hospital nurse-led smoking cessation intervention with direct referral to further follow-up in the municipal healthy life-centres (intensive intervention) or to written information about smoking cessation and the municipal program (low-threshold intervention) . The primary outcome will be the smoking cessation rates between the groups at 6 months follow-up. Key secondary outcomes include a cost-effectiveness analysis of the intensive intervention and cessation rates at 3- and 12-months follow-up, the proportion who used nicotine replacement therapy and the proportion who attended the healthy-life center program between the two groups. We also assess effects of recurrent cardiovascular events and mortality after 12 months, two and five years follow-up. Exploratory analyses include new knowledge about the patient and system factors of importance for participation to healthy life-centers and for changes in smoking behaviour.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A multi-component intervention increased access to smoking cessation treatment after hospitalization for atherosclerotic cardiovascular disease: a randomized trial.
    Pleym K, Dammen T, Wedon-Fekjaer H, Husebye E, et al · · 2024 · cited 1× · PMID 38666249 · DOI 10.1093/ehjopen/oeae028
  2. Clinical and psychosocial factors predicting persistent smoking in hospitalized patients with atherosclerotic vascular disease: A prespecified analysis of two randomized controlled trials.
    Getz V, Pleym K, Dammen T, Husebye E, et al · · 2026 · PMID 41869372 · DOI 10.18332/tpc/217328
  3. Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial.
    Pleym K, Sverre E, Weedon-Fekjær H, Kahlon MS, et al · · 2026 · PMID 41267561 · DOI 10.1111/add.70249

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

Other Vestre Viken Hospital Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05049174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing